P
Paige.AI
Building next generation computational technology that unlocks insights from each sample for doctors to optimize patient outcomes
About Paige.AI
Paige is a pioneering company in the field of digital pathology, leveraging artificial intelligence (AI) to revolutionize cancer diagnosis and treatment. The company serves pathologists, clinicians, and researchers by providing advanced insights derived from decades of data diagnosed by world-renowned cancer experts. Operating in the healthcare and biotechnology market, Paige utilizes a business model centered around AI-powered clinical decision support systems. These systems are designed to augment the capabilities of medical professionals, offering efficiencies and reproducibility in data analysis. Paige generates revenue through the sale of its AI-driven software solutions and services, which include a proprietary dataset, robust machine learning algorithms, and a unique scanner-neutral slide viewer. The company's AIRI infrastructure, boasting GPU performance of more than 10 petaFLOPS, enables the training of models at an unprecedented scale. This infrastructure supports the development of clinical-grade algorithms that provide powerful new insights for pathology and pharmaceutical development teams. Paige's AI suite is FDA 510k cleared for primary diagnosis of digital pathology slides, underscoring its clinical reliability and effectiveness.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- New York City, United States
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Pathology, Core AI, Health Diagnostics, Tech for Biotech and Pharma, Physician Support Tools, Hard Tech, AI Applications, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2025 | $81M | $81M | Tempus | ↗ |
| SERIES COther financing | Mar 2023 | $20M | $78M | Catalio Capital Management | — |
Growth signals
Latest recorded traffic for Paige.AI is 21K monthly website visits, up 5% over the last three months. Paige.AI's team declined 19.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Breyer Capital- HPHealthCor Partners
Goldman Sachs
Healthcare Venture Partners
Series B and later4 investors entered at this stage
Casdin Capital
Johnson & Johnson Innovation
KKR
Catalio Capital Management
Other known investors1 additional known investor
Tempus
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Paige.AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paige.AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.